Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The new assay consolidates screening for four major viral threats into a single workflow
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
Subscribe To Our Newsletter & Stay Updated